Trial for relapsed leukemia or risky MDS with new drug
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory AML, or relapsed/progressed high- or very-high-risk MDS
- You are age 18 or older
- Recent tests show your kidneys, liver, and other organs can handle treatment
- Your expected lifetime is at least 12 weeks, and you can do daily activities at a good level (ECOG 0–1)
- Your white blood cell count is below 50 (a medicine like hydroxyurea is allowed to help reach this)
- You can understand the study and sign (or your legal representative can sign) informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.